NIH PAR · NCATS · R21
PAR-25-442: Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease. Applicants will identify a human disease relevant undruggable target class and develop a method or agent that is selective for one or more targets within that target class. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes.
- NOFO number
- PAR-25-442
- Type
- PAR
- Activity code
- R21
- Primary institute
- NCATS · National Center for Advancing Translational Sciences
- Clinical trials
- Not Allowed
- Posted
- Jun 17, 2025
- Opens
- Sep 17, 2025
- Expires
- Feb 18, 2028
PAR-25-442 due dates
2 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| October 17, 2025 | October 17, 2025 | Not Applicable | February 2026 | May 2026 | July 2026 |
| May 15, 2026 | May 15, 2026 | Not Applicable | October 2026 | January 2027 | April 2027 |
| February 17, 2027 | February 17, 2027 | Not Applicable | June 2027 | October 2027 | December 2027 |
| February 17, 2028 | February 17, 2028 | Not Applicable | June 2028 | October 2028 | December 2028 |
Projects funded under PAR-25-442
NIH RePORTER lists 10 projects funded under PAR-25-442 in FY2022–FY2026, with $4.1M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
10
Distinct projects, FY2022–FY2026
New awards
10
Type 1 (new project) award records
NIH funding
$4.1M
Award dollars under PAR-25-442, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 10 | 10 | $4.1M |
Institutions with the most funding
- Sanford Burnham Prebys Medical Discovery Institute$536K · 1 project
- University of Chicago$451K · 1 project
- Cincinnati Childrens Hosp Med Ctr$446K · 1 project
- Indiana University Indianapolis$436K · 1 project
- Emory University$430K · 1 project
- State University of New York at Albany$430K · 1 project
- Washington University$428K · 1 project
- Tufts University Medford$375K · 1 project
Funding institutes
- NCATS$3.0M · 7
- NICHD$873K · 2
- NIAID$223K · 1
Activity codes funded
- R2110 records
Most recent new awards
- Targeting Ubiquitination to Improve Uterotonic Therapies in Postpartum Hemorrhage (opens NIH RePORTER)
Washington University · 1R21HD123143-01 · NICHD · Notice Aug 26, 2026
$428KR21
- Targeting Undruggable Lung Vascular Enhancers with Compact AAV-Cas12f CRISPR Activation (opens NIH RePORTER)
Cincinnati Childrens Hosp Med Ctr · 1R21HD123012-01 · NICHD · Notice Aug 19, 2026
$446KR21
- From Fleeting States to Therapeutics: New Perspectives in Protein-RNA Binding Dynamics and their Role in Drug Discovery (opens NIH RePORTER)
University of New Mexico · 1R21AI203185-01 · NIAID · Notice Aug 14, 2026
$223KR21
- Molecular Glue Degraders Targeting APP for Prevention and Treatment of Down Syndrome-Associated Dementia (opens NIH RePORTER)
Indiana University Indianapolis · 1R21TR006460-01 · NCATS · Notice Aug 3, 2026
$436KR21
- Targeting Undruggable SMAD4 HyperPPI with Myhre iPSC Biosensors and Organoids (opens NIH RePORTER)
Emory University · 1R21TR006421-01 · NCATS · Notice Jul 28, 2026
$430KR21
- Developing oral drugs targeting the insulin receptor using 'Beyond Rule of 5' DEL libraries (opens NIH RePORTER)
Scripps Research Institute, the · 1R21TR006406-01 · NCATS · Notice Jul 28, 2026
$369KR21
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
6 NIH institutes and offices take applications under PAR-25-442. Contact the program officer at the institute that fits your research before applying.
- NCATS · National Center for Advancing Translational Sciences
- NEI · National Eye Institute
- NIAID · National Institute of Allergy and Infectious Diseases
- NIDCR · National Institute of Dental and Craniofacial Research
- NIMH · National Institute of Mental Health
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
Related notices
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- The combined budget for direct costs for the two-year project period may not exceed 275,000. No more than 200,000 may be requested in any single year.
- Project period
- The total project period may not exceed 2 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Other open NOFOs for R21
- PAR-25-450Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)NCATS · next due Feb 17, 2027
- RFA-TR-25-002Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)NCATS
- PA-25-304NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)NIH · next due Oct 16, 2026
- PAR-25-068Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)NIDDK · next due Oct 16, 2026
- PAR-25-357NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)NEI · next due Oct 16, 2026
- PA-25-306NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)NIH · next due Oct 16, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.